300451 B-Soft Co.,Ltd.
- 4.21
- -0.12-2.77%
B-Soft Co.,Ltd. News
Venture Huikang (300451): Performance is gradually being repaired, HI-HIS is moving to a new stage of national promotion
Core view The company released the 2023 Annual Report and the 2024 First Quarter Report. In 2023, the recovery of the medical and health information technology industry fell short of expectations, and the company's profit side was under pressure, achieving operating revenue of 1,616 billion yuan, the same
Venture Huikang (300451): Q1 performance repair and Philips cooperation will enter the market development stage
Incident The company released its 2024 quarterly report, with total revenue of 375 million yuan, +7.76% year over year; net profit to mother was 12 million yuan, +19.03% year over year; net profit after deduction was 100 million yuan
Express News | Venture Huikang: The number and amount of 10 million orders in the first quarter exceeded the same period last year
Venture Huikang (300451): Medical IT business grows steadily, new products and new businesses launch at an accelerated pace
Investment events: Recently, the company released its 2023 annual report and 2024 quarterly report: (1) 2023 revenue of 1,616 billion yuan, growth rate of 5.81%, net profit to mother of 37 million yuan, a year-on-year decrease of 13.93%
Venture Huikang (300451): Performance verification, recovery expectations, HI-HIS product release can be expected
Core view: 24Q1 results are in line with recovery expectations, and sales and management expenses are optimized. The company released its 2024 quarterly report. 24Q1 achieved revenue of 380 million yuan, an increase of 7.8% over the previous year; net profit to mother was 123
Chuangye Huikang (300451.SZ) announced first-quarter results, net profit of 12.3597 million yuan, an increase of 19.03% over the previous year
Chuangye Huikang (300451.SZ) released its report for the first quarter of 2024. The company achieved operating revenue during the period...
Venture Huikang (300451): Q1 performance gradually recovers, annual profit is expected to improve
First-quarter results began to recover. The company's annual profitability or inflection point released its 2024 quarterly report, achieving operating income of 375 million yuan, an increase of 7.76% over the previous year, and a net profit of 12.36 million yuan to mother, an increase of 19 million yuan over the previous year.
Chuangye Huikang (300451) 2023 Report Review: Steady Revenue Growth HI-HIS Towards a New Stage of Promotion
Matters: On April 13, 2024, the company released its 2023 annual report: achieved operating income of 1,616 billion yuan, up 5.81% year on year; net profit to mother was 37 million yuan, down 13.93% year on year;
Southwest Securities released a research report on April 21 stating that it maintains the Venture Huikang (300451.SZ) purchase rating, and the target price is 5.20 yuan. The main reasons for the rating include: 1) revenue growth has resumed, and profits a
Southwest Securities released a research report on April 21 stating that it maintains the Venture Huikang (300451.SZ) purchase rating, and the target price is 5.20 yuan. The main reasons for the rating include: 1) revenue growth has resumed, and profits are being pressured in the short term; 2) Hi-HiS is moving towards a new stage of nationwide promotion, which is expected to accelerate the release of performance; 3) further deepening collaboration with Philips to consolidate its leading edge in many ways. (Mainichi Keizai Shimbun)
Venture Huikang (300451): HI-HIS starts large-scale promotion; increased orders support future performance
The revenue performance in 2023 was in line with our expectations, and the profit side performance was lower than our expectations. Chuangye Huikang announced the 2023 results: achieved revenue of 1,616 billion yuan, +6% year over year; net profit to mother was 37 million yuan, -14 yuan year on year
Venture Huikang (300451): Consolidate leading advantages in multiple ways and profitability is expected to be restored
Incident: The company released its 2023 annual report, achieving annual revenue of 1.62 billion yuan, a year-on-year increase of 5.8%; realized net profit of 36.689 million yuan, a year-on-year decrease of 13.9%; achieved net profit of 33 percent after deduction
Express News | 139 shares received institutional buy-in ratings, and Dongpeng Drinks received the highest level of attention
Venture Huikang (300451): Demand recovers, revenue growth awaits batch delivery by HI-HIS
Core view: The 23-year results are in line with the medical IT industry's “strong expectations, weak reality” recovery, and we are waiting for further orders to be released. The company's revenue in '23 was 1.62 billion yuan, up 5.8% year on year, maintaining a relatively steady increase
B-SOFT Co.,Ltd. Just Missed EPS By 90%: Here's What Analysts Think Will Happen Next
B-SOFT Co.,Ltd. (SZSE:300451) just released its latest yearly report and things are not looking great. It wasn't a great result overall - while revenue fell marginally short of analyst estimates
Venture Huikang (300451): Profitability is expected to recover quickly in the new phase of HI-HIS promotion
Delivery times for major projects have been extended, putting pressure on growth in 2023. The company discloses its 2023 annual report. In 2023, the company achieved revenue of 1,616 billion yuan, an increase of 5.81% year on year; net profit to mother was 37 million yuan, same as
Entrepreneurship Huikang (300451): Demand shows a positive trend and strengthens the core development ecosystem
Incident Venture Huikang released its 2023 annual report, with total operating revenue of 1,616 billion yuan, +5.81% year over year; net profit to mother was 37 million yuan, -13.93% year over year; net profit after deduction was 0.34
Entrepreneurship Huikang (300451): Revenue growth resumed for 24 years or reached an inflection point in profit
23Q4 revenue growth accelerated, and short-term profit was under pressure due to credit and asset impairment preparations. The company released the 2023 Annual Report, achieving revenue of 1,616 billion yuan, an increase of 5.81% over the previous year, and net profit of 37 million yuan to mother
Chuangye Huikang (300451.SZ): 2023 net profit of 366.885 million yuan, plans to distribute 10 to 0.1 yuan
Gelonghui, April 12: Chuanghui Huikang (300451.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 1,616 billion yuan, an increase of 5.81%; net profit attributable to shareholders of listed companies was 36.6885 million yuan, a year-on-year decrease of 13.93%; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 33.9954 million yuan, a year-on-year decrease of 27.44%; basic income per share was 0.02 yuan; it is intended to distribute a cash dividend of 0.1 yuan (tax included) to all shareholders for every 10 shares.
Venture Huikang (300451.SZ): The company will not establish its own computing power to directly serve external services, but it has already built an AI laboratory internally
Gelonghui March 12 丨 Some investors asked Chuangye Huikang (300451.SZ) on the investor interactive platform, “As the company's products advance in the cloud, does the company have established its own computing power?” The company replied that based on the accumulation of knowledge in the entrepreneurial Huikang industry, the AI product idea is to develop AI for medical informatization processes by connecting to mature third-party knowledge bases and large models. At the same time, complete the aggregation of various types of AI to form a unified platform for aggregation gateways, provide external application services, and customize overall solutions for large models for various customers. The company will not establish its own computing power to directly serve external services, but it is already internal
Chuangye Huikang (300451.SZ): At present, the company's medical device sales business has generated revenue contributions
Gelonghui March 11 丨 An investor asked Chuangye Huikang (300451.SZ) on the investor interactive platform, “Has the company's medical device sales business currently generated revenue? How much impact will it have on the performance growth of listed companies?” The company replied that at present, the company's medical device sales business has generated revenue contributions. For details on the impact on performance, please refer to the disclosure in the company's regular reports.
Analysis
Price Target
No Data
